--- title: "Determinants of Quality of Life in Pulmonary Tuberculosis: Protocol for a Systematic Review and Me" id: "bmj-open-5-factors-influencing-quality-of-life-in-patients-with-pulmonary-tuberculosis-a" canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-5-factors-influencing-quality-of-life-in-patients-with-pulmonary-tuberculosis-a" content_type: "clinical_feed_article" specialty: "Pulmonology" source_name: "BMJ Open" source_url: "http://bmjopen.bmj.com/cgi/content/short/16/8/e116725?rss=1" published_at: "2026-08-14T11:18:02.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Determinants of Quality of Life in Pulmonary Tuberculosis: Protocol for a Systematic Review and Me ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-5-factors-influencing-quality-of-life-in-patients-with-pulmonary-tuberculosis-a - **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md) - **Primary Source:** BMJ Open - **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/8/e116725?rss=1) - **Published At:** 2026-08-14T11:18:02.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) - This protocol addresses the fragmented evidence on factors influencing **quality of life (QoL)** in adults with **pulmonary tuberculosis (PTB)** and proposes a systematic review and meta-analysis to synthesise determinants. - The review is guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) statement to ensure rigorous reporting. - Eight electronic databases will be searched from inception to 30 November 2025: PubMed, Web of Science, The Cochrane Library, Embase, Scopus, China National Knowledge Infrastructure, Chinese Scientific Journals Database, and Wanfang. - Eligible studies are observational investigations of associations between potential influencing factors and QoL or health-related quality of life (HRQoL) among adult patients with PTB. - Two reviewers will independently screen records, extract data, and assess methodological quality; disagreements resolved by discussion or a third reviewer. - Meta-analysis will be undertaken only when studies are sufficiently comparable across population, factors, QoL measurement, and effect estimates; otherwise, results will be presented narratively. - Quantitative synthesis, where appropriate, will use Review Manager software; subgroup and sensitivity analyses will be performed when data permit. - No formal ethical approval is required because the review uses previously published data. - Findings will be disseminated via peer-reviewed publication and conference presentations to inform targeted nursing interventions and patient management strategies. - PROSPERO registration number provided: CRD420251196862. ## Clinical Analysis & Structured Key Points Introduction Pulmonary tuberculosis (PTB) continues to pose a significant global public health challenge and is associated with substantial physical, psychological and social burdens. Beyond traditional clinical outcomes, quality of life (QoL) has received increasing attention in PTB research and care because it reflects patients' physical, psychological and social well-being. Although several primary studies have explored factors associated with QoL among patients with PTB, the existing evidence is fragmented, with considerable variation in study populations, disease characteristics and assessment instruments. To date, no comprehensive systematic review and meta-analysis has synthesised the determinants of QoL among patients with PTB. This study aims to systematically identify, integrate and quantitatively summarise factors associated with QoL among patients with PTB, thereby providing an evidence base to inform targeted nursing interventions and patient management strategies. Methods and analysis This protocol was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols statement to ensure rigorous reporting. A systematic and comprehensive literature search will be conducted in eight electronic databases, comprising five English databases (PubMed, Web of Science, The Cochrane Library, Embase and Scopus) and three Chinese databases (China National Knowledge Infrastructure, Chinese Scientific Journals Database and Wanfang Database), from inception to 30 November 2025. Observational studies examining associations between potential influencing factors and QoL or health-related quality of life (HRQoL) among adult patients with PTB will be eligible for inclusion. Two reviewers will independently screen studies, extract data and assess methodological quality, with disagreements resolved through discussion or consultation with a third reviewer. Meta-analysis will be performed only when studies are sufficiently comparable in terms of population, influencing factors, QoL or HRQoL measurement and effect estimates; otherwise, findings will be summarised narratively. Where meta-analysis is appropriate, quantitative synthesis will be performed using Review Manager software and subgroup and sensitivity analyses will be conducted where data permit. Ethics and dissemination Since this study involves the synthesis and secondary analysis of previously published data, formal ethical approval is not required. The results of this study will be disseminated through publication in a peer-reviewed journal and presentation at relevant academic conferences. They will provide a robust evidence base for clinical nursing practice and guide the development of future research directions. PROSPERO registration number CRD420251196862. ## Related Clinical Research - [AI-driven Test-free Claims Model Predicts Trajectory Events in Fibrotic Interstitial Lung Disease](https://medichelpline.com/clinical-feed/medrxiv-5-natural-history-of-fibrotic-interstitial-lung-disease-using-ai-driven-test-free.md) - [ODN-39M and LALF32-51 as nasal adjuvants to boost immune responses to rAg85B](https://medichelpline.com/clinical-feed/biorxiv-0-synthetic-adjuvants-to-potentiate-the-immune-response-against-rag85b-by-nasal.md) - [Priority use cases for tuberculosis biomarkers and tests across infection, disease, treatment and](https://medichelpline.com/clinical-feed/medrxiv-20-defining-use-cases-for-biomarkers-and-tests-across-tuberculosis-infection.md) - [DAG-HEART: DAG-Guided Transfer Learning to Improve Equity-Aware Breast Cancer Prediction](https://medichelpline.com/clinical-feed/biorxiv-0-dag-heart-directed-acyclic-graph-guided-health-equity-aware-representation.md) - [Impact of a Person-Centered Care Intervention on HIV Treatment Reengagement in Zambia](https://medichelpline.com/clinical-feed/plos-medicine-2-effect-of-a-person-centered-care-intervention-on-return-and-sustained.md) ## Navigation - [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.